Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Cosmo Pharmaceuticals
Credit SuisseSmall & Mid Cap Conference
Zurich, 13 November 2019
Cosmo Pharmaceuticals
SAFE HARBOUR
This presentation may include forward-looking statements that are based on our management’s beliefs andassumptions and on information currently available to our management.The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any ofits plans will be achieved. Actual results may differ materially from those set forth in this presentation due to therisks and uncertainties inherent in Cosmo’s ability to develop and expand its business, successfully completedevelopment of its current product candidates and current and future collaborations for the development andcommercialization of its product candidates and reduce costs (including staff costs), the market for drugs to treatIBD diseases, Cosmo’s anticipated future revenues, capital expenditures and financial resources and othersimilar statements, may be “forward-looking” and as such involve risks and uncertainties and risks related to thecollaboration between Partners and Cosmo, including the potential for delays in the development programs forits products. No assurance can be given that the results anticipated in such forward looking statements willoccur. Actual events or results may differ materially from Cosmo’s expectations due to factors which include, butare not limited to, increased competition, Cosmo’s ability to finance expansion plans, the results of Cosmo’sresearch and development activities, the success of Cosmo’s products, regulatory, legislative and judicialdevelopments or changes in market and/or overall economic conditions. Cosmo assumes no responsibility toupdate forward-looking statements or to adapt them to future events or developments.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of thedate hereof, and Cosmo undertakes no obligation to revise or update this presentation.
2
Cosmo Pharmaceuticals
COSMO PHARMACEUTICALS NV IN A NUTSHELL
3
Market CapCHF 1.092 billion
Net Cash CHF 301 million
Value 45% Stake in Cassiopea
CHF 187 million
Employees245 Value 19.5 stake in RedHill
CHF 44 millionValue repurchased treasury shares CHF 49 million
Credit Suisse Conference 2019
1H 2019Revenues
€21.5million
Cosmo Pharmaceuticals
COSMO IN A NUTSHELL
4
Providing solutions for colon diseases
3 marketed therapeuticsLialda/MezavantUceris/Cortiment
Aemcolo/RelaFalk2 marketed
medtech products Eleview
GI Genius (EU)
Rich development pipeline
Stakes in other pharma companies:45% Cassiopea19.5% RedHill8.2% Paion2.6% Volition
Credit Suisse Conference 2019
Cosmo Pharmaceuticals
COSMO PHARMACEUTICALS: THE GI SPECIALTY COMPANY
5
Cosmo is an organization focused on improving treatment of colon diseases. Cosmo leverages its knowledge and relationships with the medical community to create shareholder value while reducing overall risks.
Gi Genius
Lialda | Mezavant | Mesavantcol
CB-03-10
Uceris | Cortiment
Credit Suisse Conference 2019
Cosmo Pharmaceuticals
C O SM O : 2019 A S A TRANSFORMATIONAL YEAR
Following delay in MB MMX approval Cosmo has:
• Completely restructured its US business, generatingsavings of € 17.5
• Completed the acquisition of 100% of Linkverse, therefore owning 100% of the AI business
• Closed the worldwide AI distribution deal with Medtronic
• Closed the US, China and South America Eleview distribution deal with Medtronic
• Closed the Collaboration Agreement with Medtronic to strengthen cooperation in AI
• Licensed Aemcolo for the USA to RedHill Biopharma and acquired a 19.56% stake in the company
Credit Suisse Conference 20196
Cosmo Pharmaceuticals
C O SM O : 2019 A S A TRANSFORMATIONAL YEA R
From the product pipeline standpoint Cosmo has:
• Filed the MB MMX Marketing AuthorizationApplication with the EMEA
• Filed the ByFavo (Remimazolam) NDA with the FDA (PDUFA April 5, 2020)
• Filed the CB-03-10 IND with the FDA• Filed the protocol for the second phase III study for
MB MMX with the FDA• Further advanced the Aemcolo Phase II Study in
IBS-D• Promoted the start of three Investigator Initiated
Phase II Studies for Aemcolo in the US for Uncomplicated Diverticulitis, Minimal HepaticEncephalopathy and Small Bacterial Overgrowth(SIBO)
7 Credit Suisse Conference 2019
Cosmo Pharmaceuticals
C O SM O : 2019 A S A TRANSFORMATIONAL YEA R
Further, Cassiopea (45% owned by Cosmo) has:
• Announced positive results from Phase III Acne Open-Label Safety Study Evaluating Winlevi®
• Announced Very Positive Phase II Twelve Months Results for Breezula®
• Filed Winlevi’s NDA with the FDA (PDUFA August 27, 2020)• Started the Breezula Phase II POC in women
8 Credit Suisse Conference 2019
Cosmo Pharmaceuticals
C O SM O : ST R AT EG Y GOING FORWARD
Following delay in approval of MB MMX in the US Cosmo has decided to shift strategy and thus to:
9
A) Enter into partnerships with selective players in exchange of equity stake and/or milestones/royalties or combination of both (Medtronic, RedHill)
B) Develop new products opportunities with partners
Credit Suisse Conference 2019
Cosmo Pharmaceuticals
As for Cassiopea, in line with the original plan and reason for spin-off, Cosmo intends to provide the necessary
financing (either equity or debt) until the approval of Winlevi
Cosmo has no long-term strategic objectives for Cassiopea, which is considered as a financial investment
that will be monetized in due course
Cosmo, upon this shift of strategy, will thoroughly reassess its need for cash in the medium term and consider options
for the eventual excess cash10 Credit Suisse Conference 2019
C O SM O : ST R AT EG Y GOING FORWARD
Cosmo Pharmaceuticals Credit Suisse Conference 201911
PRODUCT INDICATION PH I PH II PH III
Aemcolo IBS-D
Acute Uncomplicated Diverticulitis*
Small Intestine BacteriaI Overgrowth (SIBO)*
Minimal Hepatic Encephalopathy*
Byfavo Procedural Sedation
MethyleneBlue Lesion detection during colonoscopy
CB-03-10 Oral AR antagonist against solid tumors
GI-Genius Lesion detection during colonoscopy (US registration)
* Investigator Initiated Studies
C O SM O D EVEL O PM EN T PIPEL IN E
Cosmo Pharmaceuticals
THERAPEUTIC PRODUCTS
12
Cosmo Pharmaceuticals 13
Cosmo Pharmaceuticals
• Non-systemic, minimally absorbed
• MMX® delivery to the colon
• Proven efficacy against E. coli
• Reliable safety and tolerability
• Simple BID dosing
• No increase in ESBL-E colonization rates/lower
risk of acquisition
Credit Suisse Conference 201914
AEMCOLO OFFERS A CURE TO TRAVELERS’ DIARRHEA
ELIMINATING THE SHORTCOMINGS OF OTHER
TREATMENTS
1. DuPont, HL, et al. Targeting of Rifamycin SV to the Colon for Treatment of Travelers’ Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study, Journal of Travel Medicine, Vol. 21:369–376, 2014. 2. Steffen, R, et al, Rifamycin SV-MMX® for treatment of Travelers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria, Journal of Travel Medicine, 2018,
published online ahead of print, Accessed Dec 9, 2018
A EM C O L O : PER FEC TLY TAILORED FOR TRAVELERS’ D IA R R H EA 1, 2
Cosmo Pharmaceuticals
“In conclusion, no single drug is perfect against Traveler's diarrhea. We rate the advantages of non-absorbed antibiotics — reduced risk of adverse events, improvement in disease in most patients with illness, reduced risk of acquisition of multiple drug resistant organisms (so far demonstrated only for Rifamycin SV-MMX®) and lastly protection of systemic antibiotics against resistance — greater as compared to the disadvantages such as personal harm and public health impact that a small minority of Traveler's diarrhea patients with invasive illness would not be initially treated by a systemic antibiotic as first line drug from a travel kit for self-treatment.” – International Society of Travel Medicine (ISTM)
15 Credit Suisse Conference 2019
A EM C O L O FOR TRAVELERS’ D I A R R H EA : N O W R EC O M M EN D EDB Y T H E INTERNATIONAL SOC IETY OF TRAVEL M ED IC IN E ( IST M )
Cosmo Pharmaceuticals 16 Credit Suisse Conference 2019
A EM C O L O FOR TRAVELERS’ D I A R R H EA : SU PPOR TED B Y T H E F D A
Cosmo Pharmaceuticals
70MAmericans Travelling Abroad
46MVisit Developing
Countries
Prioritytargets
TRAVE LERS’ D I A R R H EA IS A H U G E M A R K ET
Credit Suisse Conference 201917
Cosmo Pharmaceuticals
TRAVELERS’ D I A R R H EA IS A H U G E M A R K ET
Credit Suisse Conference 201918
High travel spending per person in the US facilitates big commercial opportunity
https://www.aarp.org/content/dam/aarp/research/surveys_statistics/life-leisure/2017/2018-travel-trends.doi.10.26419-2Fres.00179.001.pdf
Cosmo Pharmaceuticals
• New formulation in ongoing multicenter Phase II clinical trial in Europe for IBS-D• Data expected: Q2 2020
• Further clinical development with Investigator InitiatedStudies: • Minimal Hepatic Encephalopathy
• IND and study protocol accepted by FDA• Study began in August• Acute Uncomplicated Diverticulitis• Protocol being finalized
• Small Intestine Bacterial Overgrowth (SIBO)• Protocol under development
19 Credit Suisse Conference 2019
A EM C O L O – STR ON G FU TU R E THROUGH A D D I T I O N A L INDICAT IONS
Cosmo Pharmaceuticals
A EM C O L O – OVERALL M ARKET OPPORTUNITY
• Aemcolo:• US FDA Approval for Travelers’ Diarrhea Nov. 2018• Aemcolo US Market Opportunity at least $1 billion
• Estimated market share: 20-25% • Estimated peak sales: US$200 - 250 million• Estimated time to peak sales: 7 - 8 years
• Marketed by Dr.Falk in Australia and Europe, launchin Germany December, 1st
• Marketed by RedHill in US
• Leading Competition:• US Sales of Xifaxan: US$1.3 billion• Physicians perceive advantages vs Xifaxan
20Cosmo Pharmaceuticals Credit Suisse Conference 2019
Cosmo Pharmaceuticals
THE R ED H I L L D EA L
• RedHill is a $250m mkt cap Israeli company with US operations (NASDAQ: RDHL)
• Run by a highly experienced GI management team• Rich and interesting pipeline of proprietary
products• Talicia for H pylori infection has just been approved
by the FDA• RedHill is also developing RHB-104 against
Crohn’s disease (first phase III successfullycompleted)
Credit Suisse Conference 201921
Cosmo Pharmaceuticals
THE R ED H I L L D EA L
Talicia just approved, has the potential to become a first-line therapy for H pyloriinfection, which affects over 50% of the population worldwide and approximately 35%, or over 100 million people, in the U.S., with an estimated 2.5 million patients treated annually in the US. H. pylori is classified as a Group I carcinogen by the International Agency for Research on Cancer. It is the strongest risk factor for the development of gastric cancer and a major risk factor for peptic ulcer disease and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Current standard-of-care therapies fail in approximately 25-40% of patients due to growing resistance of H. pylori to clarithromycin and metronidazole, antibiotics commonly used in standard combination therapies. Clarithromycin-resistant H. pyloriwas formally categorized by the World Health Organization (WHO) as a pathogen for which there is a high priority need to develop new treatment
Credit Suisse Conference 201922
Cosmo Pharmaceuticals
THE R ED H I L L D EA L
• Outlicense of Aemcolo for the US• Aemcolo will be promoted by a sales force of 40 reps as of now
and 140 reps as of February 2020• Down-payment of $12m in RDHL ADS (listed on NASDAQ)• Royalties in the high twenties including supply of product• Regulatory and commercial milestones totalling additional $ 100m• Take over by RedHill of all marketing activities, including digital
marketing• Shift of development responsibilities and related costs• Additional cash investment by Cosmo of $36.3m in RDHL ADS• Total investment (cash + down-payment) $48.3m, equal to 19.5%
of the share capital of RDHL
Credit Suisse Conference 201923
Cosmo Pharmaceuticals 24
Procedural sedation
Cosmo Pharmaceuticals
• Annual US colonoscopies, upper GI endoscopies
and bronchoscopies: 24.5 million
• 90% of US colonoscopies, upper GI endoscopies
and bronchoscopies used moderate sedation
• Estimated market opportunity in procedural sedation:
US$600 million
• Estimated peak sales in procedural sedation:
US$150 - 200 million
• Estimated time to peak sales: 5 - 7 years
25
US procedural sedation market only
US NDA FILED APRIL 2019 APPROVAL EXPECTED APRIL 5 2020
B YFAVO ( R EM I M A Z O L A M ) M A R K ET OPPOR T U N IT Y
Credit Suisse Conference 2019
Cosmo Pharmaceuticals 26
Lesion detection during colonoscopy
Cosmo Pharmaceuticals 27
METHYLENE BLUE MMX – US MARKET OPPORTUNITY
• 16 million US colonoscopies annually, 74% colorectal cancer related
• 12 million U.S. colorectal cancer related colonoscopies
• 31% colonoscopies in IBD patients/high risk patients• Estimated Market Opportunity: US$3 billion • Estimated peak sales: US$600 - $700 million• Estimated time line to peak sales: 7 - 8 years• Outstanding results from first phase III trial• Next steps: Ongoing discussions with FDA re
additional Phase III trial protocol• Confirmatory Phase III trial: Expected to begin Q2
2020
Credit Suisse Conference 2019
Cosmo Pharmaceuticals 28
CB-03-10Oral AR antagonist against solid tumors
Cosmo Pharmaceuticals
CB-03-10 is a highly potent AR and GR antagonist with impressive anti-tumor activity
Potential for first and second line therapy in pancreatic, colon and other cancers
Regulatory toxicology shows oral dosing is safe and well-tolerated
IND authorized by the FDA
Phase 1 clinical trial scheduled to begin Q2 2020
29
CB-03-10
Interest from potential licensing partners
Credit Suisse Conference 2019
Cosmo Pharmaceuticals
MEDTECH PRODUCT
30
Cosmo Pharmaceuticals 31
Submucosal injectable solution
Cosmo Pharmaceuticals
ELEVIEW – M A R K ET OPPORTUNITY
• 16 million US colonoscopies annually• 2.4 average polyp/patient as found in MB MMX trial: total 38.4
million lesions• 8% of polyps required injection: total injection approx. 3 million• Average 1.5 vial per removal: total 4.5 million vials• Current price: US$81 per vial• Market Opportunity approx.: US$350 million• Estimated peak sales: US$65 - 75 million (20% of market)• Time to peak sales: 7 - 8 years• US, China, South America distributor: Medtronic• Japan distributor: EA Pharma• 2018: US $11 million gross sales• US sales by Medtronic started in mid September• Medtronic will pay Cosmo 50% of sales executed in first year
to already existing customers
Credit Suisse Conference 201932
OUR REVENUES ARE PROFIT – NET MARGIN 20%
Cosmo Pharmaceuticals 33
GI GENIUSAI-enhanced endoscopy aid software
Cosmo Pharmaceuticals
GI GENIUS
• Global Distributor: Medtronic• GI Genius devices currently being deployed with EU
KOLs to prepare commercial launch• EU sales: Starting in H2 2019• To date 180 devices delivered to Medtronic for EU
deployment• US registration trial expected to begin in Q4 2019• US sales: Expected in H2 2020 following FDA approval
34
THE AI PARTNERSHIP WITH MEDTRONIC – OUR REVENUES ARE PROFITS
Credit Suisse Conference 2019
Cosmo Pharmaceuticals
GI GENIUS PRODUCT OUTLOOK
Credit Suisse Conference 201935
Cosmo Pharmaceuticals
GI GENIUS M ARKET OPPORTUNITY
Credit Suisse Conference 201936
Medtronic established business model: User
fees
Estimated initial yearly fee per endoscopy
tower US/EU: US$/€36,000
Estimated net margin for Cosmo expected
above 20%
Estimated n. of endoscopy towers in
US: 20,000
Cosmo Pharmaceuticals
THANK YOU
Cosmo Pharmaceuticals NVRiverside IISir John Rogerson’s Quay Dublin 2, [email protected]
Mr. Alessandro Della Cha , [email protected]
Mr. Niall Donnelly, [email protected]